Physician profile
Paul John Kostuchenko
NPI 1972591055
$13,274.73
in general payments reported to CMS, 2019-2025
33 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 84% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,507 · 2020: $925 · 2021: $2,238 · 2022: $2,148 · 2023: $2,552 · 2024: $2,166 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,094 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,093.64 |
| Education | $363.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,172.72 | 2019-2025 | |
| Genzyme Corporation | $1,470.85 | 2019-2025 | |
| Janssen Biotech, INC. | $1,289.94 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $962.46 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $796.90 | 2019-2025 | Ilumya, Winlevi, Blu-U |
| Pfizer INC. | $754.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $749.87 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $725.69 | 2019-2025 | |
| Ucb, INC. | $492.46 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $357.31 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $348.95 | 2023-2025 | Zoryve |
| Incyte Corporation | $336.35 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $304.37 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $290.54 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $177.59 | 2019-2025 | Nemluvio, Aklief |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $160.63 | 2019-2021 | |
| Dermavant Sciences, INC. | $134.81 | 2023-2024 | Vtama |
| Biofrontera INC. | $111.11 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Medimetriks Pharmaceuticals, INC. | $87.39 | 2021 | |
| Journey Medical Corporation | $82.92 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.76 | 2022-2024 | Spevigo |
| Mayne Pharma Commercial LLC | $57.46 | 2019-2024 | |
| Almirall LLC | $55.92 | 2020-2023 | Klisyri |
| Fresenius Kabi USA, LLC | $39.08 | 2023 | Idacio |
| Organon LLC | $38.34 | 2025 | Vtama |
| Convatec INC. | $30.26 | 2024 | |
| Aclaris Therapeutics, INC. | $23.36 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $22.93 | 2019 | |
| Genentech USA, INC. | $16.25 | 2022 | |
| Vyne Pharmaceuticals INC. | $15.91 | 2021 | |
| Botanix Sb INC | $14.73 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kostuchenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.